Biologics Quality Control Testing

Clinical
Diagnostic

Biologics Quality Control Testing

Clinical
Diagnostic

ABOUT US

PathoQuest, a spin-out of Institut Pasteur Paris, is a genomics expert company offering a game-changing next-generation sequencing (NGS) approach for microbiology testing.

The NGS-based technology the company developed is used for:

• The quality control (QC) testing of biologicals (e.g., ATMP, vaccines, antibodies), enabling rapid and robust analysis at a GLP level

• The diagnosis of infections (including sepsis) based on blood samples

PathoQuest’s technology leverages the company’s proprietary sample preparation protocols, which are applicable to several types of biological samples, proprietary internally-curated pathogen genome databases, and automated analysis pipelines.

LATEST NEWS

PathoQuest Receives GMP Certification for its NGS-based Quality Control Testing Services

PathoQuest Receives GMP Certification for its NGS-based Quality Control Testing Services

We are glad to announce today that PathoQuest has obtained a GMP certificate for its quality control testing activities at its French-based facilities in Paris (France), following a recent inspection by the French National Agency for the Safety of Medicine and Health Products (ANSM). PathoQuest is the first French CRO to offer GMP grade NGS-based testing services to assess the quality control of Human Medicinal Products and Human Investigational Medicinal Products.

read more
PathoQuest closes up to €15 million Series B financing round led by growth investor SHS Capital

PathoQuest closes up to €15 million Series B financing round led by growth investor SHS Capital

PathoQuesttoday announced the closing of a financing round up to €15M. This funding leverages the NGS technology in a proprietary approach to assess the viral safety and genetic characterization of biologics. It will support the development of PathoQuest’s US site (Wayne, PA), the expansion of the portfolio of NGS-based quality control (QC) tests and will accelerate its growth and market share worldwide.

read more
PathoQuest, recipient of French Investment Program, expands NGS-based portfolio of quality control tests for biologics

PathoQuest, recipient of French Investment Program, expands NGS-based portfolio of quality control tests for biologics

PathoQuest, has been awarded €0.85M from the French Investment Program for the Future (Programme d’Investissement d’Avenir – PIA 4). This financing will enable PathoQuest to expand its range of services with NGS-based quality control (QC) tests for the genetic characterization of biologics at a GMP (Good Manufacturing Practice) grade.

read more
w

Let’s Start Something New

Welcome to PathoQuest!